advertising
-
1
Scher RK, Coppa LM: Advances in the diagnosis and treatment of onychomycosis. Hosp Med 34: 11, 1998.
-
2
Crissey JT: Common dermatophyte infections: a simple diagnostic test and current management. Postgrad Med 103: 191, 1998.
-
3
Gupta AK, Jain HC, Lynde CW, et al: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43: 244, 2000.
-
4
Roberts DT: Onychomycosis: current treatment and future challenges. Br J Dermatol 141 (suppl 56): 1, 1999.
-
5
Finch JJ, Warshaw EM: Toenail onychomycosis: current and future treatment options. Dermatol Ther 20: 31, 2007.
-
6
Kumar S, Kimball AB: New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs 18: 727, 2009.
-
7
Jesudanam TH, Rao RG, Lakshmi DJ, et al: Onychomycosis: a significant medical problem. Indian J Dermatol Venereol Leprol 68: 326, 2002.
-
8
Ogasawara YM, Hiruma M, Muto H, et al: Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. Mycoses 46: 114, 2003.
-
9
Perea S, Ramos MJ, Garau M, et al: Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. J Clin Microbiol 38: 3226, 2000.
-
10
Roseeuw D: Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 12 (suppl 1): S6, 1999.
-
11
Haneke E, Roseeuw D: The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38 (suppl 2): 7, 1999.
-
12
Szepietowski JC, Reich A, Garlowska E, et al: Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 142: 1279, 2006.
-
13
Ungpakorn R, Lohaprathan S, Reangchainam S: Prevalence of foot diseases in outpatients attending the Institute of Dermatology, Bangkok, Thailand. Clin Exp Dermatol 29: 87, 2004.
-
14
Szepietowski JC: Selected clinical aspects of onychomycosis. Mikol Lek 11: 119, 2004.
-
15
Pierard G: Onychomycosis and other superficial fungal infections of the foot in the elderly: a pan-European survey. Dermatology 202: 220, 2001.
-
16
Zaias N, Rebell G: Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol 35: S17, 1996.
-
17
Pau M, Aste N, Biggio P: Unsuspected tinea pedis in a normal population. Micol Dermatol 5: 75, 1991.
-
18
Ingordo V, Naldi L, Fracchiola S, et al: Prevalence and risk factors for superficial fungal infections among Italian navy cadets. Dermatology 209: 190, 2004.
-
19
Elewski BE, Rich P, Pollak R, et al: Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies. J Am Acad Dermatol 68: 600, 2013.
Efinaconazole Topical Solution, 10%
Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis
Search for other papers by Bryan Markinson in
Current site
Google Scholar
PubMed
Search for other papers by Bryan Caldwell in
Current site
Google Scholar
PubMed
Background
We sought to evaluate the efficacy of efinaconazole topical solution, 10%, in patients with onychomycosis and coexisting tinea pedis.
Methods
We analyzed 1,655 patients, aged 18 to 70 years, randomized (3:1) to receive efinaconazole topical solution, 10%, or vehicle from two identical multicenter, double-blind, vehicle-controlled 48-week studies evaluating safety and efficacy. The primary end point was complete cure rate (0% clinical involvement of the target toenail and negative potassium hydroxide examination and fungal culture findings) at week 52. Three groups were compared: patients with onychomycosis and coexisting interdigital tinea pedis on-study (treated or left untreated) and those with no coexisting tinea pedis.
Results
Treatment with efinaconazole topical solution, 10%, was significantly more effective than vehicle use irrespective of the coexistence of tinea pedis or its treatment. Overall, 352 patients with onychomycosis (21.3%) had coexisting interdigital tinea pedis, with 215 of these patients (61.1%) receiving investigator-approved topical antifungal agents for their tinea pedis in addition to their randomized onychomycosis treatment. At week 52, efinaconazole complete cure rates of 29.4% were reported in patients with onychomycosis when coexisting tinea pedis was treated compared with 16.1% when coexisting tinea pedis was not treated. Both cure rates were significant compared with vehicle (P = .003 and .045, respectively), and in the latter subgroup, no patients treated with vehicle achieved a complete cure.
Conclusions
Treatment of coexisting tinea pedis in patients with onychomycosis enhances the efficacy of once-daily topical treatment with efinaconazole topical solution, 10%.
advertising
advertising
